This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lin, N. U. Articles by Winer, E. P. Search for Related Content PubMed PubMed Citation Articles by Lin, N. U. Articles by Winer, E. P. Related Collections Tumor Biology Tumor Biology: Invasion and Metastasis Clinical Research: Imaging, Diagnosis, and Prognosis

Brain Metastases: The HER2 Paradigm

Author's Affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Requests for reprints: Eric P. Winer, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Phone: 617-632-6876; Fax: 617-632-1930; E-mail: ewiner{at}partners.org.

Abstract

Between 100,000 and 170,000 patients with cancer develop central nervous system (CNS) metastases each year in the U.S., of which 20% carry a primary diagnosis of breast cancer. As a consequence of improvements in systemic therapy, which have allowed patients to live longer with advanced cancer, CNS metastases are emerging as an important sanctuary site, and the incidence may be increasing in patients with particular tumor subtypes. Unless there are improvements in the treatment of CNS disease, a growing proportion of patients may be at risk of experiencing both morbidity and mortality as a result of uncontrolled CNS progression, often at a time when their extra-CNS disease is apparently under control. This article reviews changes in the epidemiology and natural history of women with brain metastases from HER2-positive breast cancer over the last decade and presents the therapeutic challenges and opportunities that have arisen in this setting. First, the apparent increase in CNS disease among women with HER2-positive breast cancer, relative to historical controls, is discussed, followed by consideration of potential causes of this observation. Next, the implications of CNS disease, in terms of prognosis and the potential development of preventive strategies are considered. Finally, new developments in systemic approaches to the treatment of CNS disease, including cytotoxic chemotherapy and targeted therapy, are explored.

This article has been cited by other articles:

				N. U. Lin, L. A. Carey, M. C. Liu, J. Younger, S. E. Come, M. Ewend, G. J. Harris, E. Bullitt, A. D. Van den Abbeele, J. W. Henson, et al. Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer J. Clin. Oncol., April 20, 2008; 26(12): 1993 - 1999. [Abstract] [Full Text] [PDF]

				H. J. Burstein, A. M. Storniolo, S. Franco, J. Forster, S. Stein, S. Rubin, V. M. Salazar, and K. L. Blackwell A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer Ann. Onc., February 17, 2008; (2008) mdm601v1. [Abstract] [Full Text] [PDF]

				G. C. Prendergast AACR Cancer Reviews Online: A new resource for cancer researchers Cancer Reviews Online Content, April 1, 2007; 2007(1): 1 - 2. [Full Text] [PDF]

				J. B. Aragon-Ching and J. A. Zujewski CNS Metastasis: An Old Problem in a New Guise Clin. Cancer Res., March 15, 2007; 13(6): 1644 - 1647. [Abstract] [Full Text] [PDF]